This podcast is dedicated to continuous glucose monitoring (CGM) and its impact on health, inspired by German blog post #119 from Klaus Rudolf’s blog. The author explains how CGM systems work, particularly the FreeStyle Libre 3, and shares his personal experiences with the technology during a 14-day self-experiment. He examines the effects of various foods and activities on his blood sugar levels, demonstrating how CGM can help identify blood sugar spikes and detect prediabetes early on. The blog post emphasizes the importance of a healthy lifestyle and personal responsibility for one’s own health.

This podcast conversation discusses the FDA approval of a new drug called Cobenfi for the treatment of schizophrenia, inspired by the German blog post: A New Approach to Schizophrenia Treatment: Cobenfi and the Rediscovery of Xanomelin, Blog #124 from Klaus Rudolf’s blog. Cobenfi is a combination of two existing medications, Zenomalin and Trospium. Zenomalin, initially developed in the 1990s to treat Alzheimer’s disease, was later discontinued due to side effects. Trospium, a drug commonly used for overactive bladder, was added to Cobenfi to counteract these side effects. The podcast covers how the drug works and its potential impact on treating schizophrenia. It also addresses the drug’s cost and availability. Additionally, the participants underscore the ethical implications of Cobenfi and emphasize the importance of examining the effects of this medication on schizophrenia and other neurological disorders.

In this podcast, inspired by an earlier blog post (here), I reflect on my personal investment experiences across various asset classes over the past 35 years, illustrating the journey I took to build my retirement portfolio.

I provide a concise review of each investment, my ratings, and reflections on lessons learned or strategies I would approach differently today.

“Never ask a person for their opinion, forecast, or advice. Ask only what they hold in their portfolio – or don’t.” (Nassim Taleb)